Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas

Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas

Bexarotene, a drug approved for treatment of cutaneous T-cell lymphoma (CTCL), is classified as a rexinoid by its ability to act as a retinoid X receptor (RXR) agonist with high specificity. Rexinoids are capable of inducing RXR homodimerization leading to the induction of apoptosis and inhibition o...

Full description

Bibliographic Details
Main Authors: Ankedo Warda, Lech J. P. Staniszewski, Zhela Sabir, Sarah Livingston, Michael Sausedo, Sabeeha Reshi, Eyal Ron, Michael T. Applegate, Dena Haddad, Madleen Khamisi, Pamela A. Marshall, Carl E. Wagner, Peter W. Jurutka
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cells
Subjects:
rexinoids
RXR
cutaneous T-cell lymphoma
SAR
cancer
Online Access:https://www.mdpi.com/2073-4409/12/21/2575

Internet

https://www.mdpi.com/2073-4409/12/21/2575

Similar Items